Osaic Holdings
HRTX icon

Osaic Holdings’s Heron Therapeutics HRTX Stock Holding History

Osaic Holdings’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.09K Sell
3,861
-1,107
-22% -$1.28K ﹤0.01% 6890
2025
Q4 		$6.46K Buy
4,968
+1,077
+28% +$1.33K ﹤0.01% 6561
2025
Q3 		$5.25K Sell
3,891
-77
-2% -$122 ﹤0.01% 6718
2025
Q2 		$8.21K Buy
3,968
+3,000
+310% +$6.13K ﹤0.01% 6277
2025
Q1 		$2.13K Hold
968
– – ﹤0.01% 6567
2024
Q4 		$1.48K Sell
968
-441
-31% -$715 ﹤0.01% 6721
2024
Q3 		$2.8K Sell
1,409
-265
-16% -$633 ﹤0.01% 6473
2024
Q2 		$5.86K Sell
1,674
-15,508
-90% -$47.6K ﹤0.01% 6093
2024
Q1 		$47.6K Buy
17,182
+1,008
+6% +$2.53K ﹤0.01% 4789
2023
Q4 		$27.5K Sell
16,174
-2,984
-16% -$3.29K ﹤0.01% 5309
2023
Q3 		$19.7K Sell
19,158
-259
-1% -$369 ﹤0.01% 5564
2023
Q2 		$22.5K Sell
19,417
-1,571
-7% -$2.8K ﹤0.01% 5487
2023
Q1 		$31.7K Sell
20,988
-600
-3% -$1.5K ﹤0.01% 5281
2022
Q4 		$54.5K Buy
21,588
+1,341
+7% +$4.32K ﹤0.01% 4866
2022
Q3 		$85K Sell
20,247
-755
-4% -$2.95K ﹤0.01% 4506
2022
Q2 		$58K Buy
21,002
+847
+4% +$3.4K ﹤0.01% 4843
2022
Q1 		$115K Sell
20,155
-652
-3% -$4.77K ﹤0.01% 4492
2021
Q4 		$189K Sell
20,807
-21,684
-51% -$221K ﹤0.01% 3997
2021
Q3 		$456K Buy
42,491
+548
+1% +$6.67K ﹤0.01% 3120
2021
Q2 		$652K Buy
41,943
+10,308
+33% +$164K ﹤0.01% 2739
2021
Q1 		$513K Buy
31,635
+21,039
+199% +$375K ﹤0.01% 2839
2020
Q4 		$223K Buy
10,596
+2,101
+25% +$36.5K ﹤0.01% 3376
2020
Q3 		$126K Sell
8,495
-223
-3% -$3.48K ﹤0.01% 3624
2020
Q2 		$128K Buy
8,718
+6,750
+343% +$111K ﹤0.01% 3501
2020
Q1 		$23K Buy
+1,968
New +$37K ﹤0.01% 4536

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Osaic Holdings's HRTX Position: Q1 2026 in Review

Osaic Holdings reduced its Heron Therapeutics (HRTX) stake by 22% in Q1 2026, selling an estimated $1.28K and leaving 3,861 shares worth $3.09K. The position accounts for ﹤0.01% of the portfolio, ranked #6890.

Osaic Holdings first reported a position in HRTX in Q1 2020 and has held it in 25 quarters since. The position peaked at $652K in Q2 2021. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Osaic Holdings held 3,861 shares of Heron Therapeutics worth $3.09K as of Q1 2026.
  • Osaic Holdings sold 1,107 Heron Therapeutics shares in Q1 2026, an estimated $1.28K.
  • Heron Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q1 2026, its #6890 holding.
  • Osaic Holdings first reported a position in Heron Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • Osaic Holdings's Heron Therapeutics position peaked at $652K in Q2 2021.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Osaic Holdings's 13F filing for Q1 2026, filed 15 May 2026.